What's Happening?
Amgen, a biotechnology company founded in 1980, is seeking a Value & Access Senior Manager for 340B Analytics, a U.S. remote position. This role is pivotal in leading forecasting, financial modeling, and data analytics for Amgen's 340B Drug Pricing program.
The Senior Manager will be responsible for translating complex claims, payment, and policy information into brand-level forecasts, scenario analyses, and recommendations to support financial planning and business decisions. Key responsibilities include developing and refining 340B forecasts, building scenario and sensitivity analyses to quantify the impact of policy and market changes, and monitoring for anomalies and claim variances. The role also involves developing analytical capabilities, managing duplicate discount scrubbing, and partnering with various internal stakeholders such as Finance, Policy, Legal, Operations, and Coverage & Pricing to guide program strategy and execution.
Why It's Important?
This position is crucial for Amgen's strategic management of the 340B Drug Pricing program, which significantly impacts drug access and pricing for eligible healthcare providers in the U.S. Effective management of 340B analytics ensures compliance, optimizes financial performance, and helps Amgen navigate the evolving regulatory landscape. The ability to accurately forecast and model the financial impact of the 340B program is vital for the company's overall financial health and its capacity to invest in research and development for new medicines. For healthcare providers and patients, the 340B program helps reduce drug costs, and Amgen's efficient management of its participation contributes to the program's intended benefits. This role underscores the increasing complexity of pharmaceutical pricing and the need for sophisticated analytical capabilities to manage these programs effectively.
What's Next?
Amgen will proceed with the recruitment process to fill this remote Senior Manager position. Once hired, the individual will immediately begin to lead the analytical efforts for the 340B program, providing critical insights for financial planning and strategic decision-making. The ongoing evolution of healthcare policy and market dynamics will require continuous adaptation and refinement of analytical models. This role will be instrumental in ensuring Amgen's compliance and optimizing its engagement with the 340B program, which could influence the availability and affordability of its medicines for eligible entities and their patients. The company's commitment to robust analytics in this area suggests a proactive approach to managing complex regulatory and financial aspects of its business.
Beyond the Headlines
The focus on 340B analytics highlights the intricate relationship between pharmaceutical companies, government programs, and healthcare access. The 340B Drug Pricing Program, designed to help safety-net providers stretch scarce federal resources, has become a significant and often debated component of the U.S. healthcare system. The need for a dedicated Senior Manager for analytics reflects the program's complexity, including issues like duplicate discounts, evolving regulations, and the financial impact on both manufacturers and providers. This role also touches upon broader themes of drug pricing transparency, healthcare affordability, and the ethical considerations of ensuring equitable access to life-saving medications. The insights generated from this analytical function could inform Amgen's broader strategies for patient access and corporate social responsibility.













